F. Haab, G. Amarenco, P. Coloby, P. Grise, B. Jacquetin et al., Terminology of lower urinary tract dysfunction: French adaptation of the terminology of the International Continence Society], Prog Urol. déc, vol.14, issue.6, pp.1103-1114, 2004.

F. Haab, Chapter 1: The conditions of neurogenic detrusor overactivity and overactive bladder, Neurourology and Urodynamics, vol.30, issue.S3, pp.2-5, 2014.
DOI : 10.1002/nau.22636

A. Ruffion, D. Castro-­?diaz, H. Patel, K. Khalaf, A. Onyenwenyi et al., Systematic Review of the Epidemiology of Urinary Incontinence and Detrusor Overactivity among Patients with Neurogenic Overactive Bladder, Neuroepidemiology, vol.41, issue.3-4, pp.3-4146, 2013.
DOI : 10.1159/000353274

E. Mcguire, J. Woodside, T. Borden, and R. Weiss, Prognostic value of urodynamic testing in myelodysplastic patients, The Journal of Urology, vol.167, issue.2, pp.1049-53, 1981.
DOI : 10.1016/S0022-5347(02)80338-X

R. Boissier and G. Karsenty, Pronostic des vessies neurologiques, Progr??s en Urologie, vol.23, issue.14, pp.1181-1186, 2013.
DOI : 10.1016/j.purol.2013.09.023

J. Pannek and B. Kullik, Does Optimizing Bladder Management Equal Optimizing Quality of Life? Correlation Between Health-related Quality of Life and Urodynamic Parameters in Patients With Spinal Cord Lesions, Urology, vol.74, issue.2, pp.263-269, 2009.
DOI : 10.1016/j.urology.2009.02.047

M. Schneider, T. Gross, L. Bachmann, B. Blok, D. Castro-­?diaz et al., Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review, European Urology, vol.68, issue.5
DOI : 10.1016/j.eururo.2015.07.001

V. Keppene, P. Mozer, E. Chartier-­?kastler, and A. Ruffion, Neuromodulation dans la prise en charge des troubles v??sico-sphinct??riens neurologiques, Progr??s en Urologie, vol.17, issue.3, pp.609-624, 2007.
DOI : 10.1016/S1166-7087(07)92376-3

R. Caremel, J. Cornu, J. Kerdraon, E. Bastide, C. Bruyere et al., Les m??dicaments de la vessie, Progr??s en Urologie, vol.23, issue.15, pp.1271-86, 2013.
DOI : 10.1016/j.purol.2013.09.020

P. Madhuvrata, M. Singh, and Z. Hasafa, Anticholinergic Drugs for Adult Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis, European Urology, vol.62, issue.5
DOI : 10.1016/j.eururo.2012.02.036

P. Abrams, L. Cardozo, S. Khoury, and W. A. , Incontinence: 5th International Consultation on Incontinence, p.2013

A. Nambiar and M. Lucas, Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO), Neurourology and Urodynamics, vol.184, issue.S3, pp.21-26, 2014.
DOI : 10.1002/nau.22631

J. Duthie, M. Vincent, G. Herbison, D. Wilson, and D. Wilson, Botulinum toxin injections for adults with overactive bladder syndrome, Cochrane Database Syst Rev, issue.12, p.5493, 2011.

B. Perrouin-­?verbe, A. Ruffion, X. Gamé, P. Denys, J. Kerdraon et al., Crit??res de d??cision et recommandations de bonne pratique clinique pour la premi??re injection intrad??trusorienne de toxine botulique A dans le traitement de l???hyperactivit?? neurog??ne du d??trusor, Progr??s en Urologie, vol.19, issue.6, pp.372-82, 2009.
DOI : 10.1016/j.purol.2009.02.006

P. Grise, Y. Daoudi, Y. Tanneau, and L. Sibert, Use and mechanism of botulinum toxin in overactive bladder treatment], Ann Urol (Paris). sept, vol.39, pp.3-4105, 2005.

G. Karsenty, J. Corcos, B. Schurch, A. Ruffion, and E. Chartier-­?kastler, Chapitre C-l C - Traitement pharmacologique de l???hyperactivit?? d??trusorienne neurologique : injections intra-d??trusoriennes de toxine botulique A, Progr??s en Urologie, vol.17, issue.3, pp.568-75, 2007.
DOI : 10.1016/S1166-7087(07)92370-2

D. Dykstra, A. Sidi, A. Scott, J. Pagel, and G. Goldish, Effects of botulinum A toxin on detrusor-­?sphincter dyssynergia in spinal cord injury patients, J Urol. mai, vol.139, issue.5, pp.919-941, 1988.

B. Schurch, M. Stöhrer, G. Kramer, D. Schmid, G. Gaul et al., BOTULINUM-A TOXIN FOR TREATING DETRUSOR HYPERREFLEXIA IN SPINAL CORD INJURED PATIENTS: A NEW ALTERNATIVE TO ANTICHOLINERGIC DRUGS? PRELIMINARY RESULTS, The Journal of Urology, vol.164, issue.3, pp.692-699, 2000.
DOI : 10.1016/S0022-5347(05)67283-7

A. Mangera, K. Andersson, A. Apostolidis, C. Chapple, P. Dasgupta et al., Contemporary Management of Lower Urinary Tract Disease With Botulinum Toxin A: A Systematic Review of Botox (OnabotulinumtoxinA) and Dysport (AbobotulinumtoxinA), European Urology, vol.60, issue.4, pp.784-95, 2011.
DOI : 10.1016/j.eururo.2011.07.001

R. Rosales, H. Bigalke, and D. Dressler, Pharmacology of botulinum toxin: differences between type A preparations, European Journal of Neurology, vol.296, issue.Suppl. 8, pp.2-10, 2006.
DOI : 10.1111/j.1468-1331.2006.01438.x

J. Grosse, G. Kramer, and M. Stöhrer, Success of Repeat Detrusor Injections of Botulinum A Toxin in Patients with Severe Neurogenic Detrusor Overactivity and Incontinence, European Urology, vol.47, issue.5, pp.653-662, 2005.
DOI : 10.1016/j.eururo.2004.11.009

R. Veeratterapillay, C. Harding, L. Teo, N. Vasdev, A. Abroaf et al., Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type???A injections for detrusor overactivity, International Journal of Urology, vol.58, issue.12, pp.175-183, 2014.
DOI : 10.1111/iju.12205

P. Grise, A. Ruffion, P. Denys, G. Egon, C. Kastler et al., Efficacy and Tolerability of Botulinum Toxin Type A in Patients with Neurogenic Detrusor Overactivity and Without Concomitant Anticholinergic Therapy: Comparison of Two Doses, European Urology, vol.58, issue.5, pp.759-66, 2010.
DOI : 10.1016/j.eururo.2010.06.035

S. Shakeri, R. Mohammadian, A. Aminsharifi, A. Ariafar, J. Vaghedashti et al., Success rate and patients' satisfaction following intradetrusor dysport injection in patients with detrusor overactivity: a comparative study of idiopathic and neurogenic types of detrusor overactivity, Urol J. févr, vol.11, issue.1, pp.1289-95, 2014.

I. Ghalayini and M. , Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: Urodynamic outcome and patient satisfaction, Neurourology and Urodynamics, vol.38, issue.4, pp.531-537, 2007.
DOI : 10.1002/nau.20403

D. Popolo, G. Filocamo, M. Marzi, V. Macchiarella, A. Cecconi et al., Neurogenic Detrusor Overactivity Treated with English Botulinum Toxin A: 8-Year Experience of One Single Centre, European Urology, vol.53, issue.5, pp.1013-1022, 2008.
DOI : 10.1016/j.eururo.2007.09.034

P. Ravindra, B. Jackson, and R. Parkinson, ) make a difference?, BJU International, vol.103, issue.1, pp.94-103, 2013.
DOI : 10.1111/bju.12028

A. Do-nascimento-remigio, A. Salles, J. De-faria, and M. Ferreira, Comparison of the Efficacy of OnabotulinumtoxinA and AbobotulinumtoxinA at the 1, Plastic and Reconstructive Surgery, vol.135, issue.1, pp.239-288, 2015.
DOI : 10.1097/PRS.0000000000000800

J. Yun, J. Kim, H. Kim, S. Chung, J. Kim et al., Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: A double-blind, randomized study, Movement Disorders, vol.12, issue.Suppl 8, pp.206-219, 2015.
DOI : 10.1002/mds.26085

V. Annese, G. Bassotti, G. Coccia, D. 'onofrio, V. Gatto et al., Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia, Alimentary Pharmacology and Therapeutics, vol.48, issue.10, pp.1347-50, 1999.
DOI : 10.1002/(SICI)1097-4598(1997)6+<146::AID-MUS10>3.0.CO;2-4

R. Kassir, A. Kolluru, and M. Kassir, Triple-Blind, Prospective, Internally Controlled Comparative Study Between AbobotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Facial Rhytids, Dermatology and Therapy, vol.12, issue.5 Suppl, pp.179-89, 2013.
DOI : 10.1007/s13555-013-0033-y

B. Mohammadi, S. Balouch, R. Dengler, and K. Kollewe, Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients, Neurological Research, vol.4, issue.2, pp.309-322, 2010.
DOI : 10.1177/154596830101500108

B. Peyronnet, S. Sanson, G. Amarenco, E. Chartier-­?kastler, E. Charvier et al., Definition of botulinum toxin failure in neurogenic detrusor overactivity: Preliminary results of the DETOX survey], Prog Urol. 26 août, 2015.

P. Injection, Oui Non Si oui lequel et à quelles doses : Capacité Cystomanométrique Maximale Pression détrusorienne Maximale Volume à la 1ère contraction détrusorienne non Inhibée Modalités de la 1 ère injection -Date de 1 ère injection, Dose totale de Botox®injectée (UI): -Nombre de site d'injection

. La-posologie-de, Botox® a-t-elle été augmentée lors de la dernière injection

. Critères-définissant-l-'échec and . Botox®, à analyser pour chaque dossier / chaque équipe -la question peut être posée à chaque équipe en dehors de l'analyse dossier/dossier : comment définissez vous l'échec de toxine dans cette indication) -Clinique : persistance de fuites (sans fuite d'effort), infections répétées

. La-posologie-de, Dysport® a-t-elle été augmentée lors de la dernière injection